Price T Rowe Associates Inc. MD Purchases 4,409 Shares of Emergent BioSolutions Inc. (NYSE:EBS)

Price T Rowe Associates Inc. MD lifted its holdings in Emergent BioSolutions Inc. (NYSE:EBS) by 22.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 23,943 shares of the biopharmaceutical company’s stock after purchasing an additional 4,409 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Emergent BioSolutions were worth $61,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Allspring Global Investments Holdings LLC increased its holdings in shares of Emergent BioSolutions by 1.5% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 460,289 shares of the biopharmaceutical company’s stock worth $1,105,000 after buying an additional 6,724 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Emergent BioSolutions by 84.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,873,984 shares of the biopharmaceutical company’s stock worth $6,898,000 after acquiring an additional 1,312,934 shares during the last quarter. Jump Financial LLC purchased a new stake in Emergent BioSolutions during the fourth quarter valued at approximately $58,000. Dynamic Technology Lab Private Ltd purchased a new stake in Emergent BioSolutions during the fourth quarter valued at approximately $232,000. Finally, Oxford Asset Management LLP purchased a new position in shares of Emergent BioSolutions in the 4th quarter worth approximately $67,000. Institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Stock Performance

Shares of NYSE:EBS opened at $10.74 on Monday. The company has a current ratio of 1.08, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67. Emergent BioSolutions Inc. has a 12 month low of $1.42 and a 12 month high of $15.10. The company has a market capitalization of $562.80 million, a price-to-earnings ratio of -0.98 and a beta of 1.62. The firm’s 50-day moving average is $8.91 and its 200 day moving average is $5.14.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($1.35). Emergent BioSolutions had a negative return on equity of 18.53% and a negative net margin of 47.68%. The business had revenue of $254.70 million during the quarter, compared to analysts’ expectations of $199.47 million. During the same quarter in the previous year, the company posted ($1.06) earnings per share. Research analysts predict that Emergent BioSolutions Inc. will post -1.98 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Benchmark restated a “buy” rating and set a $8.00 price target on shares of Emergent BioSolutions in a report on Friday.

Insider Transactions at Emergent BioSolutions

In other news, Director Kathryn C. Zoon sold 10,000 shares of the company’s stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $6.11, for a total value of $61,100.00. Following the transaction, the director now directly owns 54,482 shares in the company, valued at $332,885.02. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last ninety days, insiders sold 12,919 shares of company stock worth $75,831. 1.20% of the stock is currently owned by insiders.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.